# US 2016/0367555 A1 · Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0367555 A1
- Document ID: US20160367555A1
- Status: Published application
- Kind: A1
- Application number: 15/158,171
- Filed: 2016-05-18
- Published: 2016-12-22
- Earliest claimed: 2010-08-26
- Assignees: Symphony Evolution, Inc.
- Inventors: Philip Frost; William W. N. Liao; Eric K. Rowinsky
- Web page: https://patentgrep.com/patent/US20160367555A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention comprises a method of treating polycystic kidney disease (PKD) in a mammal, such as a human or feline (e.g., Persian cat), comprising administering a therapeutically effective amount of the compound of formula to the mammal. Also provided are uses of the compound for preparation of a medicament for treating PKD and the above compound and compositions comprising it for treating PKD.

## Claims

### Claim 1

A method of treating polycystic kidney disease (PKD) in a mammal, the method comprising administering a therapeutically effective amount of a compound of formula
or a pharmaceutically acceptable salt thereof, to a mammal having PKD,
wherein the administering of the compound or pharmaceutically acceptable salt thereof is by way of a tablet or liquid dosage form.

### Claim 2 (depends on 1)

The method of claim 1 wherein the dosage form is a tablet.

### Claim 3 (depends on 2)

The method of claim 2 wherein the compound or pharmaceutically acceptable salt thereof is 50 wt % of the tablet.

### Claim 4 (depends on 2)

The method of claim 2 wherein the tablet comprises 50 mg of the compound or pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4 wherein the compound or pharmaceutically acceptable salt thereof is 50 wt % of the tablet.

### Claim 6 (depends on 2)

The method of claim 2 wherein the mammal is a human.

### Claim 7 (depends on 2)

The method of claim 2 wherein the mammal is a feline.

### Claim 8 (depends on 7)

The method of claim 7 wherein the feline is a Persian cat.

### Claim 9 (depends on 2)

The method of claim 2 wherein the mammal is a human.

### Claim 10 (depends on 2)

The method of claim 2 wherein the mammal is a feline.

### Claim 11 (depends on 10)

The method of claim 10 wherein the feline is a Persian cat.

### Claim 12 (depends on 4)

The method of claim 4 wherein the mammal is a human.

### Claim 13 (depends on 5)

The method of claim 5 wherein the mammal is a human.

### Claim 14 (depends on 2)

The method of claim 2 wherein the tablet comprises the following components and amounts:
Component
Amount (% w/w)
the compound or pharmaceutically
50.00
acceptable salt thereof
Lactose Monohydrate
25.70
Microcrystalline Cellulose
10.00
Hypromellose
3.00
Crospovidone
7.00
Sodium Lauryl Sulfate
3.00
Colloidal Silicon Dioxide
0.70
Magnesium Stearate
0.60

### Claim 15 (depends on 14)

The method of claim 14 wherein the tablet comprises 50 mg of the compound or pharmaceutically acceptable salt thereof and the mammal is a human.

### Claim 16 (depends on 2)

The method according to claim 2 wherein the administration is once daily.

### Claim 17 (depends on 7)

The method according to claim 7 wherein the administration is once daily.

### Claim 18 (depends on 12)

The method according to claim 12 wherein the administration is once daily.

### Claim 19 (depends on 13)

The method according to claim 13 wherein the administration is once daily.

### Claim 20 (depends on 14)

The method according to claim 14 wherein the administration is once daily.

### Claim 21 (depends on 15)

The method according to claim 15 wherein the administration is once daily.

### Claim 22 (depends on 1)

The method according to claim 1 wherein the dosage form is a liquid.

### Claim 23 (depends on 22)

The method according to claim 22 wherein the liquid dosage form is a water-based solution.

### Claim 24 (depends on 23)

The method according to claim 23 wherein the formulation is administered in an amount of 0.3 to 6 mg of the compound to kg of the mammal.

### Claim 25 (depends on 24)

The method of claim 24 wherein the mammal is a human.

### Claim 26 (depends on 24)

The method of claim 24 wherein the mammal is a feline.

### Claim 27 (depends on 25)

The method of claim 25 wherein the feline is a Persian cat.
